Jennifer Kayden Lee - 11 Feb 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: EVP, Head of North America
Signature: /s/ Hunter Smith, Attorney-in-Fact for Jennifer Chien
Issuer symbol: RYTM
Transactions as of: 11 Feb 2023
Net transactions value: -$17,062
Form type: 4
Filing time: 14 Feb 2023, 19:59:28 UTC
Previous filing: 14 Feb 2023
Next filing: 09 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise		+2,031	+57%		5,575	11 Feb 2023	Direct	F1
transaction	RYTM	Common Stock	Sale	$17,062	-635	-11%	$26.87	4,940	14 Feb 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Options Exercise	$0	-2,031	-33%	$0.000000	4,062	11 Feb 2023	Common Stock	2,031		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3	The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.